Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Yasuchika Hasegawa

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Gut instincts lead Takeda to GI pipeline success

Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy

- PMLiVE

Merck gets first approval for MET inhibitor tepotinib in Japan

First worldwide approval for MET inhibitor

- PMLiVE

Takeda begins development of COVID-19 plasma therapy

Drug will harness the antibodies of recovered coronavirus patients

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links